EE200100253A - 2,4-diasendatud triasiiniderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus - Google Patents

2,4-diasendatud triasiiniderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus

Info

Publication number
EE200100253A
EE200100253A EEP200100253A EEP200100253A EE200100253A EE 200100253 A EE200100253 A EE 200100253A EE P200100253 A EEP200100253 A EE P200100253A EE P200100253 A EEP200100253 A EE P200100253A EE 200100253 A EE200100253 A EE 200100253A
Authority
EE
Estonia
Prior art keywords
preparation
combination
product
pharmaceutical composition
triazine derivatives
Prior art date
Application number
EEP200100253A
Other languages
English (en)
Estonian (et)
Inventor
Adriaan Jan Janssen Paul
Joseph Kukla Michael
De Corte Bart
Ren De Jonge Marc
Heeres Jan
W. Kavash Robert
Maria Henricus Koymans Lucien
William Ludovici Donald
Jeanne Alfons Van Aken Koen
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200100253A publication Critical patent/EE200100253A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100253A 1998-11-10 1999-11-04 2,4-diasendatud triasiiniderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus EE200100253A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779998P 1998-11-10 1998-11-10
EP99203128 1999-09-24
PCT/EP1999/008688 WO2000027828A2 (en) 1998-11-10 1999-11-04 2,4-disubstituted triazine derivatives with anti hiv activity

Publications (1)

Publication Number Publication Date
EE200100253A true EE200100253A (et) 2002-12-16

Family

ID=26153374

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100253A EE200100253A (et) 1998-11-10 1999-11-04 2,4-diasendatud triasiiniderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus

Country Status (35)

Country Link
US (2) US6638932B1 (xx)
EP (1) EP1129079B1 (xx)
JP (1) JP2002529457A (xx)
KR (1) KR100620402B1 (xx)
CN (1) CN1207290C (xx)
AP (1) AP1636A (xx)
AR (1) AR021137A1 (xx)
AT (1) ATE315031T1 (xx)
AU (1) AU764472B2 (xx)
BG (1) BG65160B1 (xx)
BR (1) BR9915176A (xx)
CA (1) CA2351203C (xx)
CY (1) CY1105596T1 (xx)
CZ (1) CZ20011532A3 (xx)
DE (1) DE69929354T2 (xx)
DK (1) DK1129079T3 (xx)
EA (1) EA004501B1 (xx)
EE (1) EE200100253A (xx)
ES (1) ES2257081T3 (xx)
HK (1) HK1038232A1 (xx)
HR (1) HRP20010310A2 (xx)
HU (1) HUP0104395A3 (xx)
ID (1) ID28545A (xx)
IL (2) IL143024A0 (xx)
MY (1) MY126781A (xx)
NO (1) NO319788B1 (xx)
NZ (1) NZ510919A (xx)
OA (1) OA11675A (xx)
PL (1) PL196523B1 (xx)
PT (1) PT1129079E (xx)
SI (1) SI1129079T1 (xx)
SK (1) SK6022001A3 (xx)
TR (1) TR200101319T2 (xx)
TW (1) TW541305B (xx)
WO (1) WO2000027828A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027828A2 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. 2,4-disubstituted triazine derivatives with anti hiv activity
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
ES2311146T3 (es) * 2003-02-07 2009-02-01 Janssen Pharmaceutica Nv 1,2,4-triazinas que inhiben el vih.
US7923554B2 (en) 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
GB201204756D0 (en) * 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4927592B1 (xx) 1970-05-13 1974-07-18
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4650867A (en) 1985-03-26 1987-03-17 Ciba-Geigy Corporation Process for the preparation of 2,4,6-tris(aminophenylamino)triazines
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
CA2174080A1 (en) 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
WO2000027828A2 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. 2,4-disubstituted triazine derivatives with anti hiv activity

Also Published As

Publication number Publication date
NO319788B1 (no) 2005-09-12
CN1207290C (zh) 2005-06-22
BG65160B1 (bg) 2007-04-30
US6638932B1 (en) 2003-10-28
TR200101319T2 (tr) 2001-10-22
IL143024A (en) 2006-06-11
SI1129079T1 (sl) 2006-06-30
IL143024A0 (en) 2002-04-21
TW541305B (en) 2003-07-11
DK1129079T3 (da) 2006-05-15
HRP20010310A2 (en) 2002-06-30
AP1636A (en) 2006-07-17
EP1129079B1 (en) 2006-01-04
CZ20011532A3 (cs) 2001-10-17
DE69929354D1 (de) 2006-03-30
AU1046200A (en) 2000-05-29
NO20011934L (no) 2001-04-19
BR9915176A (pt) 2001-08-14
HUP0104395A3 (en) 2003-02-28
JP2002529457A (ja) 2002-09-10
CN1325387A (zh) 2001-12-05
PL196523B1 (pl) 2008-01-31
EA200100534A1 (ru) 2001-10-22
ID28545A (id) 2001-05-31
ES2257081T3 (es) 2006-07-16
DE69929354T2 (de) 2006-09-14
KR100620402B1 (ko) 2006-09-13
OA11675A (en) 2005-01-12
US7015221B2 (en) 2006-03-21
HUP0104395A2 (hu) 2002-04-29
EP1129079A2 (en) 2001-09-05
WO2000027828A2 (en) 2000-05-18
CA2351203A1 (en) 2000-05-18
KR20010075234A (ko) 2001-08-09
CA2351203C (en) 2009-03-24
WO2000027828A3 (en) 2000-09-21
MY126781A (en) 2006-10-31
US20050277641A1 (en) 2005-12-15
SK6022001A3 (en) 2002-01-07
AR021137A1 (es) 2002-06-12
AU764472B2 (en) 2003-08-21
HK1038232A1 (en) 2002-03-08
NO20011934D0 (no) 2001-04-19
EA004501B1 (ru) 2004-04-29
PL348145A1 (en) 2002-05-06
NZ510919A (en) 2003-11-28
ATE315031T1 (de) 2006-02-15
PT1129079E (pt) 2006-05-31
BG105419A (en) 2001-11-30
CY1105596T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
EE9700253A (et) Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
HUP0104582A3 (en) 1,2-annelated quinoline derivatives, pharmaceutical compositions thereof, intermediates and process for their preparation
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
HUP0103567A3 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
EE200000620A (et) 3-(amino- või aminoalküül)püridinooni derivaadid,nende valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE03767B1 (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
HUP0102400A3 (en) Substituted octalydropyrido[1,2a]pyrazin derivatives and pharmaceutical compositions containing the same
HUP0104026A3 (en) 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
EE04398B1 (et) Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiin-10-oolid, nende valmistamise meetod ja kasutamine ravimitena
HUP0103533A3 (en) Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use
HUP0202433A3 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists, process for producing them and pharmaceutical compositions containing them
EE200100253A (et) 2,4-diasendatud triasiiniderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
HUP0101234A3 (en) Betha-carboline derivatives, process for their preparation and pharmaceutical compositions thereof
EE200100209A (et) Tritsüklilised 3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE200200331A (et) Hargnenud ahelaga asendatud 3-amino-1-fenüül-1H-[1,2,4]triasooli aminoderivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid